Angiogenic factors for the prediction of preeclampsia in high-risk women

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 3, 2007, Pages 244.e1-244.e8

  Moore Simas, Tiffany A ^a   Crawford, Sybil L ^a   Solitro, Matthew J ^a   Frost, Sara C ^a   Meyer, Bruce A ^a   Maynard, Sharon E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

angiogenic factors; placental growth factor; preeclampsia; soluble fms like tyrosine kinase 1

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; ONSET AGE; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 34548446787     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.06.030     Document Type: Article

References (21)

1. World Health Organization. World health report: make every mother and child count (2005), World Health Organization, Geneva
2. Saftlas A.F., Olson D.R., Franks A.L., Atrash H.K., and Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 163 (1990) 460-465
3. Duckitt K., and Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330 (2005) 565
4. Eskenazi B., Fenster L., and Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA 266 (1991) 237-241
5. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
6. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award. Am J Obstet Gynecol 190 (2004) 1541-1550
7. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
8. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
9. McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., and McClure N. Soluble vascular endothelial growth factor receptor-1 (sflt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191 (2004) 1240-1246
10. Wathen K.A., Tuutti E., Stenman U.H., et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 91 (2006) 180-184
11. American College of Obstetricians and Gynecologist practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99 (2002) 159-167
12. Alexander G.R., Kogan M., Martin J., and Papiernik E. What are the fetal growth patterns of singletons, twins, and triplets in the United States?. Clin Obstet Gynecol 41 (1998) 114-125
13. American College of Obstetricians and Gynecologist committee opinion. Antenatal corticosteroid therapy for fetal maturation. American College of Obstetricians and Gynecologist. Int J Gynaecol Obstet 78 (2002) 95-97
14. Diggle P., and Liang K.-Y. Analysis of longitudinal data (1994), Clarendon Press, Oxford, England
15. Margolis D.J., Bilker W., Boston R., Localio R., and Berlin J.A. Statistical characteristics of area under the receiver operating characteristic curve for a simple prognostic model using traditional and bootstrapped approaches. J Clin Epidemiol 55 (2002) 518-524
16. Efron B. The jackknife, the bootstrap, and other sampling plans (1982), Society for Industrial and Applied Mathematics, Philadelphia
17. Solitro M., Moore Simas T., Frost S., Rajan A., Crawford S., and Maynard S.E. Circulating soluble fms-like tyrosine kinase-1 (sFlt1) is increased in multiple gestation vs. singleton pregnancies (2006) Presented at the 39th Annual Meeting of the American Society of Nephrology, San Diego, CA.
18. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007)
19. Vatten L.J., Eskild A., Nilsen T.I., Jeansson S., Jenum P.A., and Statt A.C. Changes in circulating levels of angiogenic factors from the first to second trimesters as predictors of preeclampsia. Am J Obstet Gynecol 196 (2007) 239.e1-239.e6
20. Altman D., Carroli G., Duley L., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate?. The Magpie trial: a randomised placebo-controlled trial. Lancet 359 (2002) 1877-1890
21. Barratt A., Irwig L., Glasziou P., et al. Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group. JAMA 281 (1999) 2029-2034